Vera Therapeutics reports incentive grants pursuant to Nasdaq Listing Rule 5635(c)(4)

BRISBANE, Calif., Sept. 10, 2024 (GLOBE NEWSWIRE) — Vera Therapeutics, Inc. (Nasdaq: VERA) today announced that on September 5, 2024, the Compensation Committee granted incentive awards in the form of a non-qualified stock option to purchase 21,750 shares of Class A common stock and restricted stock units (RSUs) for 9,875 shares of Class A common stock to two new employees under the Incentive Plan. The Compensation Committee approved the awards as an incentive for the hiring of the new employees in accordance with Nasdaq Listing Rule 5635(c)(4).

The stock option granted on September 5, 2024 has an exercise price per share of $38.16, Vera's closing price on September 5, 2024. Each stock option will vest over a four-year period, with 25% of the underlying shares vesting on the first anniversary of the respective vesting commencement date and the remainder of the underlying shares vesting monthly for 36 months thereafter, subject to the new employee's continued employment relationship with Vera through the respective vesting dates. Each of the RSUs will vest over a four-year period, with 25% of the underlying shares vesting on each anniversary of November 20, 2024, subject to the new employee's continued employment relationship with Vera through the respective vesting dates. The awards are subject to the terms of the Incentive Plan and the terms of an applicable award agreement covering the award.